This drug maker's kidney disease treatment scores $50M payday
FibroGen Inc. will receive $50 million from partner AstraZeneca after federal regulators accepted the San Francisco company's application to approve a drug for treating anemia in chronic kidney disease patients. Acceptance of FibroGen's new drug application for the drug, called roxadustat, by the Food and Drug Administration means AstraZeneca plc (NYSE: AZN) must pay $50 million to FibroGen, the company said in a Securities and Exchange Commission filing Tuesday. Roxadustat, an oral small-molecule… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 12, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

This drug maker's kidney disease treatment scores $50M payday
FibroGen Inc. will receive $50 million from partner AstraZeneca after federal regulators accepted the San Francisco company's application to approve a drug for treating anemia in chronic kidney disease patients. Acceptance of FibroGen's new drug application for the drug, called roxadustat, by the Food and Drug Administration means AstraZeneca plc (NYSE: AZN) must pay $50 million to FibroGen, the company said in a Securities and Exchange Commission filing Tuesday. Roxadustat, an oral small-molecule… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 12, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Janssen Announces Submission to U.S. FDA for New DARZALEX ® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “W...
Source: Johnson and Johnson - February 10, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pulses for a Sustainable Future
By Zoltán KálmánROME, Feb 10 2020 (IPS) Reducing poverty and inequalities, eliminating hunger and all forms of malnutrition and achieve food insecurity for all – these are some of the most important objectives of the Sustainable Development Goals. Still, the rate of poverty and inequalities is increasing and over 820 million people are going hungry. In addition, 2 billion people in the world are food insecure with great risk of malnutrition and poor health. This alarming situation is further aggravated by current trends such as the rate of population growth, impacts of climate change, loss of bio...
Source: IPS Inter Press Service - Health - February 10, 2020 Category: International Medicine & Public Health Authors: Zoltan Kalman Tags: Climate Change Development & Aid Economy & Trade Environment Featured Food & Agriculture Global Headlines Health Human Rights Humanitarian Emergencies Inequity Natural Resources Poverty & SDGs TerraViva United Nations Source Type: news

Geography, age and anemia shape childhood vaccine responses in Sub-Saharan Africa
(American Association for the Advancement of Science) Vaccine responses in the developing immune systems of children may depend on factors such as age, location and anemia status, according to a study comparing samples from 1,119 Dutch children to 171 children in sub-Saharan Africa who took part in a malaria vaccine trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 6, 2020 Category: International Medicine & Public Health Source Type: news

Development of the immune system varies according to age, location and anaemia
(Barcelona Institute for Global Health (ISGlobal)) Age and geographical location have the strongest influence on immune composition and vaccine responses, with anaemia having a considerable effect, according to a study co-led by the Barcelona Institute for Global Health (ISGlobal), the Babraham Institute and the Swiss Tropical and Public Health Institute, in collaboration with the Manhi ç a Health Research Center (CISM). The results, published in Science Translational Medicine, will help improve the efficacy of early childhood vaccines in low-income countries. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 5, 2020 Category: Infectious Diseases Source Type: news

New understanding of childhood immune systems may improve vaccine efficacy
(Swiss Tropical and Public Health Institute) In low- and middle-income countries, children have the greatest need for protection afforded by vaccination due to high incidence of infectious diseases. However, vaccines for these children show lower efficacy when compared to similar populations in high-income settings. A study by Swiss TPH and partners from Babraham Institute and ISGlobal published in Science Translational Medicine reveals that the immune system of children varies according to age, location and anaemia status. This knowledge is crucial to improve vaccine efficacy. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 5, 2020 Category: Infectious Diseases Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Do You Do For Breast Milk Jaundice?
Discussion Almost all infants in the first few days of life have some elevation of their bilirubin because of the various physiologic changes they undergo in the transition to extra-uterine life. This is a common problem managed by many different inpatient and outpatient healthcare providers. This hyperbilirubinemia is usually unconjugated and resolves in the first 1-2 weeks of life. However, when it does not resolve, health care providers have 3 general paths to follow when considering a cause: inadequate breast milk intake, an underlying organic cause or breast milk jaundice. Inadequate breastfeeding is not uncommon and...
Source: PediatricEducation.org - February 3, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Balancing safety and potential for impact in universal iron interventions - Baldi AJ, Larson LM, Pasricha SR.
Almost 300 million children under 5 years of age are anemic worldwide. International policymakers recommend universal distribution of iron-based interventions - either iron supplements or iron-containing multiple micronutrient powders - to alleviate the bu... (Source: SafetyLit)
Source: SafetyLit - January 30, 2020 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Monoferric(R) (Ferric Derisomaltose) Injection Is Approved by the US FDA for the Treatment of Iron Deficiency Anemia
MORRISTOWN, N.J., Jan. 29, 2020 -- (Healthcare Sales & Marketing Network) -- Pharmacosmos Therapeutics Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Monoferric® (ferric derisomaltose) injection 100 mg/mL. M... Biopharmaceuticals, FDA Pharmacosmos Therapeutics, Monoferric, ferric derisomaltose, anemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 29, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Monoferric (ferric derisomaltose) Injection for the Treatment of Iron Deficiency Anemia
MORRISTOWN, N.J., Jan. 29, 2020 /PRNewswire/ -- Pharmacosmos Therapeutics Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Monoferric® (ferric derisomaltose) injection 100 mg/mL. ... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 29, 2020 Category: Drugs & Pharmacology Source Type: news

Anticoagulation and Anemia: Opponents From the Era of VKA? Anticoagulation and Anemia: Opponents From the Era of VKA?
A new study indicates that the antithrombotic efficacy of NOACs are reduced in anemic patients. Should patients with AF and moderate to severe anemia receive oral anticoagulants?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Engineered capillaries model traffic in tiny blood vessels
(University of Washington Health Sciences/UW Medicine) 3D microvessels have been created to observe how red blood cells transit ultra-small blood vessels. They squeeze single-file through microvessels to bring oxygen and nutrients. Red cells burdened with malaria stall, blocking the blood vessel. The platform is expected to have other uses in studies of how microvascular damage occurs in diabetes and sickle cell anemia. They might be further developed to supply blood circulation to organ repair patches or to 3D printed transplants. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 23, 2020 Category: International Medicine & Public Health Source Type: news

While promoting diseases like cancer, these enzymes also cannibalize each other
(Georgia Institute of Technology) In diseases like cancer, atherosclerosis, and sickle cell anemia, cathepsins promote their propagation. Drug trials to inhibit these enzymes have failed due to baffling side effects. Now a new study examines cathepsins in systems to remove some of the bafflement. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 20, 2020 Category: Cancer & Oncology Source Type: news

Zydus & CMS enter pact for Desidustat in Greater China
The agreement is for Desidustat, a novel oral HIF-PH inhibitor for the treatment of anemia in patients with Chronic Kidney Disease (CKD) not-on-dialysis and for the treatment of anemia CKD patients on dialysis in Greater China, Zydus said in a statement. "Under the license agreement, CMS will pay Zydus an initial upfront payment," it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 20, 2020 Category: Pharmaceuticals Source Type: news

Association between anemia and maternal depression: a systematic review and meta-analysis - Kang SY, Kim HB, Sunwoo S.
Previous observational epidemiological studies have reported inconsistent findings regarding the association between anemia and the risk of maternal depression. In the present study, we investigated the relationship between anemia and the risk of maternal ... (Source: SafetyLit)
Source: SafetyLit - January 18, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Vitamin B12 deficiency: The sign on your legs and feet that could signal you are deficient
Vitamin B12 is an essential nutrient that the body absorbs through eating certain foods but certain conditions hinder the body ’s ability to absorb the nutrient, which can lead to a deficiency. Pernicious anaemia is a common underlying cause of a B12 deficiency and a certain symptom associated with the legs and feet may signal you have it. (Source: Daily Express - Health)
Source: Daily Express - Health - January 13, 2020 Category: Consumer Health News Source Type: news

When Heavy Periods Disrupt a Teenager ’s Life
“Someone’s menstrual period should not be impairing them from leading a normal life, because we have really good treatments for pain and for heavy bleeding,” an expert says. (Source: NYT Health)
Source: NYT Health - January 13, 2020 Category: Consumer Health News Authors: Perri Klass, M.D. Tags: Menstruation Estrogen Hormones Women and Girls Parenting Anemia Birth Control and Family Planning Source Type: news

At 16, She ’s a Pioneer in the Fight to Cure Sickle Cell Disease
Helen Obando is the youngest person ever to get a gene therapy that scientists hope will cure the disease, which afflicts 100,000 Americans. (Source: NYT Health)
Source: NYT Health - January 12, 2020 Category: Consumer Health News Authors: Gina Kolata Tags: Sickle Cell Anemia Genetics and Heredity Genetic Engineering Stem Cells Clinical Trials Boston Children ' s Hospital Bluebird Bio Source Type: news

A Teenager ’s Breakthrough Gene Therapy for Sickle Cell Disease
Doctors reset Helen Obando ’s DNA in an effort to cure her of a painful genetic blood disorder. She’s the youngest person to receive the treatment. (Source: NYT Health)
Source: NYT Health - January 10, 2020 Category: Consumer Health News Tags: Sickle Cell Anemia DNA (Deoxyribonucleic Acid) Genetics and Heredity Boston Children ' s Hospital Clinical Trials FX (TV Network) Hulu.com The Weekly (TV Program) Source Type: news

Sickle Cell Disease (Anemia)
Title: Sickle Cell Disease (Anemia)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 1/10/2020 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - January 10, 2020 Category: Anesthesiology Source Type: news

Vitamin B12 deficiency symptoms: Three signs you may have pernicious anaemia
VITAMIN B12 deficiencies affect around 6 percent of people in the UK and the condition is recognised by the World Health Organisation as a global health problem that could impact millions of lives. Having a severe B12 deficiency could be caused by pernicious anaemia. These are the three main signs you may be at risk of the condition. (Source: Daily Express - Health)
Source: Daily Express - Health - January 9, 2020 Category: Consumer Health News Source Type: news

Luspatercept Mitigates Anemia in Lower - Risk Myelodysplastic Syndromes
Transfusion burden reduced in patients with lower - risk myelodysplastic syndromes with ring sideroblasts (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 9, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Luspatercept Mitigates Anemia in Lower-Risk Myelodysplastic Syndromes
WEDNESDAY, Jan. 8, 2020 -- For patients with lower-risk myelodysplastic syndromes with ring sideroblasts who have been receiving regular red-cell transfusions, luspatercept reduces the severity of anemia compared with placebo, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 8, 2020 Category: Pharmaceuticals Source Type: news

Four months after CEO's death, biotech company names Lilly vet as leader
Enrique Conterno, a 27-year veteran of Eli Lilly and Co., was named Monday as the new CEO of FibroGen Inc., stepping into a role vacated with the death of founder, chairman and CEO Thomas Neff on Aug. 25. The 64-year-old Neff died unexpectedly after the 500-employee San Francisco company he founded in 1993 won its first regulatory approval, for the drug roxadustat, in China. The company also lined up approvals in Japan, Europe and the United States to treat anemia in chronic kidney disease patients ;… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 7, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Four months after CEO's death, biotech company names Lilly vet as leader
Enrique Conterno, a 27-year veteran of Eli Lilly and Co., was named Monday as the new CEO of FibroGen Inc., stepping into a role vacated with the death of founder, chairman and CEO Thomas Neff on Aug. 25. The 64-year-old Neff died unexpectedly after the 500-employee San Francisco company he founded in 1993 won its first regulatory approval, for the drug roxadustat, in China. The company also lined up approvals in Japan, Europe and the United States to treat anemia in chronic kidney disease patients ;… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 7, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Impact of injury severity on the inflammatory state and severe anemia - Apple CG, Miller ES, Loftus TJ, Kannan KB, Parvataneni HK, Hagen JE, Efron PA, Mohr AM.
BACKGROUND: Severe traumatic injury is a major cause of morbidity and mortality. Our goal was to analyze blunt traumatic injury by injury severity score (ISS) and compare with elective hip repair, as a transient injury, and healthy control with the hypothe... (Source: SafetyLit)
Source: SafetyLit - December 31, 2019 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Hepatitis gene therapy leads Bay Area trio of year-end FDA approval requests
Approaching the end of long drug-development journeys, these three Bay Area companies formally asked the FDA to approve potential treatments for hemophilia A, anemia in chronic kidney disease patients and migraines. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 23, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Hepatitis gene therapy leads Bay Area trio of year-end FDA approval requests
Approaching the end of long drug-development journeys, these three Bay Area companies formally asked the FDA to approve potential treatments for hemophilia A, anemia in chronic kidney disease patients and migraines. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 23, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease
SAN FRANCISCO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for roxadustat for the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 23, 2019 Category: Drugs & Pharmacology Source Type: news

Eligible for two schemes but these patients still can't get money for transplants
Eleven-year-old Sameer from Bihar ’s Muzaffarpur district is suffering from aplastic anaemia, and needs Rs 12 lakh for a bone marrow transplant. You would think that’s not a big hurdle since his mother’s name figures in the list of Ayushman Bharat beneficiaries but unfortunately his condition isn’t covered by the scheme. (Source: The Economic Times)
Source: The Economic Times - December 22, 2019 Category: Consumer Health News Source Type: news

The Future of Health in Tajikistan Starts with Community Health Volunteers
By Casey Bishopp, Communications officer, IntraHealth International ; Roman Yorick , Chief of Party, Tajikistan Health and Nutrition Activity Community health volunteers work across maternal and child health, hygiene, agriculture, and advocacy in Tajikistan's Khatlon region. Photo by Claudia Muir for IntraHealth International.December 18, 2019Roman Yorick and his team in Tajikistan have plenty to be proud of.Yorick leads IntraHealth International’s work there, where we address maternal and child health through nutrition and agricultural programs and work to improve hygiene and sanitation in health care faciliti...
Source: IntraHealth International - December 18, 2019 Category: International Medicine & Public Health Authors: cbishopp Tags: Maternal, Newborn, & Child Health Nutrition IntraHealth ' s 40th Anniversary Community Health Workers Source Type: news

Address Malnutrition, Not Just Food Security
By Jomo Kwame Sundaram, Wan Manan Muda and Tan Zhai GenKUALA LUMPUR, Malaysia, Dec 17 2019 (IPS) Malnutrition remains a formidable challenge in most societies, with less than a tenth of countries in the world not experiencing at least one major malnutrition problem. In relatively more food secure countries, where almost everyone has enough to eat, and few live in fear of a sudden loss of access to food, micronutrient deficiencies and diet-related non-communicable diseases (NCDs) often still loom large. Jomo Kwame SundaramOne such country is Malaysia where rice is, by and large, available and affordable to almost everyone...
Source: IPS Inter Press Service - Health - December 17, 2019 Category: International Medicine & Public Health Authors: Jomo Kwame Sundaram - Wan Manan Muda and Tan Zhai Gen Tags: Asia-Pacific Development & Aid Economy & Trade Featured Food & Agriculture Headlines Health Human Rights Poverty & SDGs TerraViva United Nations Trade & Investment Women's Health Source Type: news

Nigeria: Meet Your Match - J Blood Artificial Intelligence Connects Blood Donors to Receivers in the FCT
[Nigeria Health Watch] Is there an alternative to blood for humans? The answer is no.One of the most vital requirements for a woman experiencing severe bleeding during childbirth is a blood transfusion. It is also the most essential need of a child suffering from severe anaemia due to chronic malnutrition or malaria. Accident victims, organ transplant patients and others often require blood transfusions to keep them alive, and blood transfusion is only possible with the availability of safe blood at the point of need. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 17, 2019 Category: African Health Source Type: news

What Are Some Potential Adverse Effects of Blood Donation?
Discussion Just under 40% of people are eligible to be a blood donor. Up to 6.5% of a population are actual donors. “Blood donors are healthy volunteers who give either whole blood or blood components by apheresis including platelets, plasma, red blood cells, peripheral blood stem cells and leucocytes or a combination of blood components. They represent a large, healthy population exposing themselves voluntarily for altruistic, sometimes financial motives to potential complications and risks.” Blood banking systems world-wide are responsible for caring for individual donors health as well as maintaining a robus...
Source: PediatricEducation.org - December 16, 2019 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Dana-Farber Study: New Drugs Show Rare Promise Against Advanced Breast Cancer
SAN ANTONIO (AP) — Doctors on Wednesday reported unusually good results from tests of two experimental drugs in women with an aggressive form of breast cancer that had spread widely and resisted many previous treatments. One drug showed particular ability to reach tumors in the brain, which are notoriously tough to treat. The other pairs a sort of homing device for cancer cells with a payload of chemotherapy that’s released when it reaches its target. “It’s a guided missile. It’s able to bring the chemotherapy directly to the cancer cell,” said the study leader, Dr. Ian Krop of the Dana-...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 11, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Breast Cancer Dana Farber Cancer Institute Source Type: news

Cochrane systematic review informs WHO guidelines, policy
Originally published in the Cornell ChronicleFolate is an essential B-vitamin that is needed for DNA synthesis and cell division. Folate deficiency can lead to anemia, and deficiency early in pregnancy can lead to neural tube defects – birth defects of the brain, spine and spinal cord, including spina bifida.A Cochrane systematic review on the benefits and safety of fortifying wheat or maize flour with folic acid and population health outcomes, led by scientists in the  Division of Nutritional Sciences at Cornell, found that fortification with folic acid (the synthetic form of folate) may improve folate sta...
Source: Cochrane News and Events - December 10, 2019 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Vitamin B12 deficiency: Feeling this sensation in the chest could mean pernicious anaemia
VITAMIN B12 is one of the main "raw materials" needed to build the healthy red blood cell; the other is folate or folic acid. In order to make healthy red blood cells that can carry oxygen around the body a person needs adequate levels of B12. Feeling this sensation in your chest is a warning sign of pernicious anaemia. (Source: Daily Express - Health)
Source: Daily Express - Health - December 10, 2019 Category: Consumer Health News Source Type: news

Folate (vitamin B9) deficiency anemia: Causes, symptoms, risk factors, treatment and prevention
(Natural News) Folate, often referred to as folic acid or vitamin B9, is an essential nutrient found in many green leafy vegetables and fresh fruits. It plays a critical role in various bodily processes, such as producing red blood cells, as well as creating and repairing DNA. Not getting enough folate could lead to unwanted health complications, one... (Source: NaturalNews.com)
Source: NaturalNews.com - December 9, 2019 Category: Consumer Health News Source Type: news

How Does Gaucher Disease Present?
Discussion Gaucher disease (GD) was first described by Philippe Gaucher in 1882. It was the first lysosomal storage disease (LSD) described and is the comparison prototype for many variations and their treatment. There are about 50 LSD and more well-known ones include Fabry, Niemann-Pick and Pompe diseases. LSDs currently have more than 300 different enzymes or membrane proteins affected which cause central nervous system and visceral disease. Overall the frequency of LSDs in aggregate is 1:3000 – 7000 live births. GD has an estimated prevalence of 1:57,000 – 111,000. It is higher within the Ashkenazi Jewish po...
Source: PediatricEducation.org - December 9, 2019 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Two New Drugs Help Relieve Sickle-Cell Disease. But Who Will Pay?
Adakveo and Oxbryta could be revolutionary treatments, but each costs about $100,000 per year and must be taken for life. (Source: NYT Health)
Source: NYT Health - December 7, 2019 Category: Consumer Health News Authors: Gina Kolata Tags: Drugs (Pharmaceuticals) Health Insurance and Managed Care Sickle Cell Anemia Prices (Fares, Fees and Rates) Stroke Clinical Trials Hemoglobin Food and Drug Administration Novartis AG Global Blood Therapeutics Source Type: news

A potential Diamond-Blackfan anemia treatment swims into view
(Boston Children's Hospital) Zebrafish share about 70 percent of their genes with humans, and can be studied at a mass scale, enabling scientists to test hundreds, even thousands of drugs at a time simply by adding the drug to their water. One such test came up with a new potential treatment for a rare blood disorder, Diamond-Blackfan anemia (DBA): a drug called trifluoperazine, normally used to treat psychotic disorders. It's now in a clinical trial for DBA in adults. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2019 Category: International Medicine & Public Health Source Type: news

Yellow fever – Bolivarian Republic of Venezuela
On 13 November 2019, the Venezuela International Health Regulations (IHR) National Focal Point (NFP) and the Venezuela PAHO/WHO Country Office shared information about a confirmed case of yellow fever in Bolivar State. The case-patient is a 46-year-old male resident of the municipality of Gran Sabana, Bolivar State. He was in the locality of Uriman municipality of Gran Sabana within the 19 days prior to the onset of symptoms. Symptom onset was on 14 September 2019, and included fever, chills, nausea, vomiting, epistaxis, petechiae, and diarrhoea. On 26 September 2019, he visited a public hospital in the municipality of Her...
Source: WHO Disease Outbreaks - November 21, 2019 Category: Infectious Diseases Tags: news Source Type: news

Tajik Community Health Volunteers Improve Nutrition, Maternal Health, and Agriculture for Thousands
November 14, 2019Thousands of people in Tajikistan's Khatlon region now have greater access to health services, nutrition, and sanitation, thanks toFeed the Future Tajikistan Health& Nutrition Activity (THNA), implemented by IntraHealth International.In the twelve districts where IntraHealth conducts the USAID-funded work, in partnership with Abt Associates, widespread malnutrition leads to stunting, anemia, and poor maternal and child health, while infrastructure for proper sanitation and hygiene remains inadequate.THNA recruited and trained 1,300 health volunteers and 500 agriculture volunteers.To mitigate these issu...
Source: IntraHealth International - November 14, 2019 Category: International Medicine & Public Health Authors: mnathe Tags: Tajikistan Feed the Future Tajikistan Health and Nutrition Activity Maternal, Newborn, & Child Health Community Engagement Health Workforce Systems Primary Health Care Community Health Workers Source Type: news

Reblozyl Approved to Treat Anemia in Patients With Beta Thalassemia
WEDNESDAY, Nov. 13, 2019 -- Reblozyl (luspatercept-aamt) has been approved to treat anemia in adults with beta thalassemia who require regular red blood cell (RBC) transfusions, the U.S. Food and Drug Administration announced Friday. Reblozyl is... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 13, 2019 Category: General Medicine Source Type: news

Scientists identify immune cells linked to malaria-induced anaemia through autoantibody production
(eLife) An autoimmune attack on uninfected red blood cells likely contributes to anaemia -- a shortage of red blood cells -- in people with malaria, according to a new study published in eLife. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 12, 2019 Category: Infectious Diseases Source Type: news

FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
SUMMIT, N.J.& CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 9, 2019 Category: Drugs & Pharmacology Source Type: news

Celgene's drug for anemia in beta thalassemia priced at $3,441/ 25 mg vial
Celgene Corp's treatment for anemia in patients with beta thalassemia, a rare blood disorder, would be priced at $3,441 for a 25-milligram vial of the drug, partner Acceleron Pharma Inc said. (Source: Reuters: Health)
Source: Reuters: Health - November 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Safety data on AstraZeneca anemia drug points to potential use in dialysis
AstraZeneca said on Friday that safety data on roxadustat underpinned the British drugmaker's hopes for the anemia drug to become a standard treatment for patients with kidney disease. (Source: Reuters: Health)
Source: Reuters: Health - November 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news